UroGen PharmaURGN
Recorded

UroGen Pharma 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration59 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Thank you for standing by, and welcome to UroGen Pharma's third quarter 2026 earnings conference call. Currently, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. To remove yourself from the queue, you may press star 11 again. I would now like to hand the call over to Vincent Perrone, Senior Director of Investor Relations. Please go ahead. Thank you.

Vincent PerroneSenior Director of Investor Relations

Good morning, everyone, and welcome to UroGen Pharma's third quarter 2026 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended September 30, 2026. The release can be accessed on the investors portion of our website at investors.urogen.com. Joining me today are Liz Barrett, President and Chief Executive Officer, Dr. Mark Schoenberg, Chief Medical Officer, and Chris Degnan, Chief Financial Officer. On today's call, we will be making certain forward-looking statements.

Vincent PerroneSenior Director of Investor Relations

These may include statements regarding our ongoing commercialization activities related to ZUSDURI and JELMYTO, our ongoing and planned clinical trials and non-clinical studies, commercial and clinical development milestones, market and revenue opportunities, our commercialization strategy and expectations, as well as anticipated data, regulatory filings and decisions, the importance of ZUSDURI's growth for UroGen's long-term strategy, anticipated benefits of our strategic collaboration with IntraGel Therapeutics, the potential benefits of our products and product candidates, future R&D efforts and milestones, our corporate goals, and 2026 financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and UroGen disclaims any obligation to update these statements.

Vincent PerroneSenior Director of Investor Relations

I'll now turn the call over to Liz Barrett, Chief Executive Officer.

Liz BarrettPresident and CEO

Liz? Good morning, and thank you for joining us today.

Liz BarrettPresident and CEO

We delivered another quarter of strong execution, with ZUSDURI generating $68 million in net product revenue, representing a 35% sequential quarter-over-quarter growth. More importantly, the underlying commercial trends continue to strengthen, with increasing repeat utilization, broader physician adoption, and continued expansion into community practices. Together, these trends reinforce our confidence that ZUSDURI is scaling successfully and establishing a strong foundation for sustained growth. This momentum reflects ZUSDURI's differentiated value proposition. As the first and only FDA-approved medicine for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, ZUSDURI offers a primary surgery-free alternative for a disease that historically has been managed through repetitive surgical interventions. We believe this differentiated approach provides patients an opportunity to have more recurrence-free and treatment-free living, and is increasingly changing how physicians think about treating these patients.

Liz BarrettPresident and CEO

Turning to the operating metrics we have been tracking, as of September 30, 2026, we had over 1,500 activated accounts. With a substantial foundation of activated accounts now in place, our commercial team's focus is shifting toward driving utilization within these practices, converting new prescribers into repeat users, and expanding adoption across the broader physician community. Unique prescribers grew to 662, compared with 452 in the second quarter, while repeat prescribers increased to 331, compared to 204 at the end of the prior period. Repeat prescribers now represent 50% of total writers, up from 45% in the second quarter and 40% in Q1. We continue to view repeat utilization as one of the strongest indicators of sustained adoption. As physicians gain experience with ZUSDURI's clinical profile, reimbursement process, and administration workflow, they become increasingly comfortable incorporating the product into routine practice.

Liz BarrettPresident and CEO

We believe this growing familiarity and confidence will deepen utilization over time. We continue to see encouraging adoption trends across community urology practices, with the site of care mix remaining relatively consistent with the second quarter, and community practices accounting for the majority of the utilization. This reflects the progress we've made in expanding our presence in the community setting, where approximately 70% of our addressable market resides. We believe continued growth and deeper penetration within these practices represent a significant opportunity to sustain momentum as the launch continues. We are also expanding demand generation efforts through physician education, peer-to-peer programs, and patient awareness initiatives. Many patients living with recurrent low-grade non-muscle invasive bladder cancer remain unaware that a surgery-free treatment option is available.

Liz BarrettPresident and CEO

We believe direct-to-patient efforts can encourage more informed discussions between patients and providers, while peer-to-peer programs may help physicians gain confidence from colleagues with firsthand experience using ZUSDURI. Together, we expect these investments to support broader adoption and help realize the significant commercial opportunity ahead. During the third quarter, we did observe some anticipated summer seasonality for a short period, but bounced back quickly as reflected by the strong quarter results. Importantly, continued growth in new prescribers and patient starts more than offset these seasonal dynamics, reinforcing the underlying strength of demand. Looking ahead to the fourth quarter, remain mindful of typical holiday-related slowdown, but continue to see opportunities to expand adoption and utilization and expect quarter-over-quarter revenue growth. Turning to JELMYTO, net product revenue was $21 million in the third quarter, compared with $22 million in the second quarter.

Liz BarrettPresident and CEO

Importantly, this included a one-time unfavorable gross-to-net adjustment of approximately $1.5 million related to the CMS discarded drug provision true-up. We are also seeing increased competition for eligible patients from ongoing clinical trials in the low-grade UTUC space, including our own UGN-104 phase III trial, which has created some headwinds for patient starts. Nevertheless, JELMYTO remains an important surgery-free treatment option for patients with low-grade UTUC and continues to support our broader commercial infrastructure. Turning now to the pipeline, we achieved an important milestone with UGN-103, our next-generation investigational therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Following our NDA submission in August, the FDA accepted the application for review in October and assigned a PDUFA goal date of June 14, 2027, representing another significant step toward potential approval. UGN-103 is a central component to our longer-term strategy.

Liz BarrettPresident and CEO

It is designed to build on the clinical and commercial foundation of ZUSDURI while offering potential manufacturing and operational efficiencies that can further strengthen our business over time and opportunities to expand into other non-muscle invasive bladder cancer populations. Importantly, our newly issued patent, now listed in the FDA's Orange Book, is expected to provide patent coverage into July of 2044 for both ZUSDURI and, if approved, UGN-103 for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer without a TURBT. We believe this further strengthens the long-term revenue potential for both products. Beyond the initial indication, our planned expansion into high-grade NMIBC with UGN-103 represents an additional opportunity to broaden our reach and address unmet needs in uro-oncology. As part of our lifecycle management strategy for UGN-103, we also plan to initiate a non-registrational trial evaluating its use as an adjuvant therapy in the newly diagnosed intermediate-risk population.

Liz BarrettPresident and CEO

Mark will discuss the regulatory and clinical plans in greater detail shortly. Finally, in August, we announced a strategic collaboration, licensing option, and equity investment agreement with IntraGel Therapeutics, representing an exciting expansion of our innovation and growth strategy. The agreement provides access to IntraGel's biodegradable sustained-release platform and gives us the opportunity to develop up to three new oncology products using this technology, while also securing an exclusive option to acquire worldwide rights to their cisplatin gel-based phase II-ready therapy for advanced head and neck cancer. Importantly, this collaboration expands our capability beyond uro-oncology while remaining aligned with our core expertise in localized sustained drug delivery. We believe it creates meaningful opportunity to broaden our pipeline, advance innovation across additional solid tumors, and supports future growth. In closing, the progress we made through the first nine months of 2026 has strengthened our confidence in the opportunity ahead.

Liz BarrettPresident and CEO

ZUSDURI continues to scale, our next-generation programs are advancing toward important milestones, and we are investing in a pipeline that we believe can support multiple drivers of future growth. We are building a company positioned for sustained growth through commercial execution, lifecycle expansion, and continued innovation. With over $90 million in cash on the balance sheet at quarter end, we remain confident in our ability to reach profitability with our existing capital resources. Above all, our strategy remains grounded in our commitment to patients and the belief that they deserve better treatment options. We see tremendous opportunity to build on our success in uro-oncology, expand our reach into additional specialty cancers, and create meaningful long-term value for our shareholders. With that, I'll turn the call over to Mark for a clinical update.

Mark SchoenbergChief Medical Officer

Mark? Thank you, Liz, and good morning, everyone.

Mark SchoenbergChief Medical Officer

I would like to begin by building on Liz's discussion on how ZUSDURI adoption is evolving, particularly as physicians gain experience and increasingly incorporate the product into routine clinical practice. From a clinical perspective, what makes ZUSDURI particularly compelling is that it offers a fundamentally different approach to managing adult patients with recurrent low-grade intermediate-risk NMIBC. It is the only FDA-approved primary therapy in this setting, and unlike other therapies currently in development, it does not require TURBT as part of the treatment regimen. For patients who have historically faced repeated surgeries under general anesthesia and prolonged treatment courses, the ability to achieve durable disease control without another TURBT represents a meaningful advancement. This distinction becomes increasingly important as the treatment landscape evolves. Many investigational therapies are being evaluated as adjuvant treatments following TURBT, often requiring additional induction and maintenance therapy over extended periods.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day